Fusion Pharmaceuticals Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 28.18 million compared to USD 24.62 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.55 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.42 USD | +0.09% | +0.75% | +122.89% |
EPS Revisions
- Stock Market
- Equities
- FUSN Stock
- News FUSN PHAR
- Fusion Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023